Tiniakou E, Casciola-Rosen L, Thomas M, Manabe Y, Antar A, Damarla M
Clin Transl Immunology. 2024; 13(12):e70019.
PMID: 39734590
PMC: 11671454.
DOI: 10.1002/cti2.70019.
Al Qureshah F, Le Pen J, de Weerd N, Moncada-Velez M, Materna M, Lin D
J Exp Med. 2024; 222(2).
PMID: 39680367
PMC: 11648951.
DOI: 10.1084/jem.20241413.
Baran A, Atilgan Lulecioglu A, Gao L, Yazici Y, Demirel F, Metin A
J Clin Immunol. 2024; 45(1):48.
PMID: 39579251
PMC: 11821294.
DOI: 10.1007/s10875-024-01843-1.
Rosain J, Le Voyer T, Liu X, Gervais A, Polivka L, Cederholm A
J Exp Med. 2024; 221(11).
PMID: 39352576
PMC: 11448874.
DOI: 10.1084/jem.20231152.
Arango-Franco C, Ogishi M, Unger S, Delmonte O, Orrego J, Yatim A
J Clin Invest. 2024; 134(19).
PMID: 39352394
PMC: 11444196.
DOI: 10.1172/JCI180251.
A sensitive assay for measuring whole-blood responses to type I IFNs.
Gervais A, Le Floch C, Le Voyer T, Bizien L, Bohlen J, Celmeli F
Proc Natl Acad Sci U S A. 2024; 121(40):e2402983121.
PMID: 39312669
PMC: 11459193.
DOI: 10.1073/pnas.2402983121.
Dangers of Herpesvirus Infection in SLE Patients Under Anifrolumab Treatment: Case Reports and Clinical Implications.
Larsen M, Skouboe M, Mogensen T, Lund Laursen A, Deleuran B, Troldborg A
Am J Case Rep. 2024; 25:e944505.
PMID: 39245905
PMC: 11393608.
DOI: 10.12659/AJCR.944505.
Human genetic and immunological determinants of SARS-CoV-2 infection and multisystem inflammatory syndrome in children.
Kholaiq H, Abdelmoumen Y, Moundir A, El Kettani A, Ailal F, Benhsaien I
Clin Exp Immunol. 2024; 219(1).
PMID: 39028583
PMC: 11771195.
DOI: 10.1093/cei/uxae062.
Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies.
Fernbach S, Mair N, Abela I, Groen K, Kuratli R, Lork M
J Exp Med. 2024; 221(9).
PMID: 39017930
PMC: 11253716.
DOI: 10.1084/jem.20240365.
The ouroboros of autoimmunity.
Casanova J, Peel J, Donadieu J, Neehus A, Puel A, Bastard P
Nat Immunol. 2024; 25(5):743-754.
PMID: 38698239
DOI: 10.1038/s41590-024-01815-y.
Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID-19 Patients.
Aoki A, Iwamura C, Kiuchi M, Tsuji K, Sasaki A, Hishiya T
J Clin Immunol. 2024; 44(4):104.
PMID: 38647550
PMC: 11035476.
DOI: 10.1007/s10875-024-01708-7.
The immunopathological landscape of human pre-TCRα deficiency: From rare to common variants.
Materna M, Delmonte O, Bosticardo M, Momenilandi M, Conrey P, Charmeteau-De Muylder B
Science. 2024; 383(6686):eadh4059.
PMID: 38422122
PMC: 10958617.
DOI: 10.1126/science.adh4059.
Type I Interferon Autoantibodies Correlate With Cellular Immune Alterations in Severe COVID-19.
Strunz B, Maucourant C, Mehta A, Wan H, Du L, Sun D
J Infect Dis. 2024; 230(2):e318-e326.
PMID: 38421006
PMC: 11326830.
DOI: 10.1093/infdis/jiae036.
Human autoantibodies neutralizing type I IFNs: From 1981 to 2023.
Bastard P, Gervais A, Le Voyer T, Philippot Q, Cobat A, Rosain J
Immunol Rev. 2024; 322(1):98-112.
PMID: 38193358
PMC: 10950543.
DOI: 10.1111/imr.13304.
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children.
Bastard P, Gervais A, Taniguchi M, Saare L, Sarekannu K, Le Voyer T
J Exp Med. 2024; 221(2).
PMID: 38175961
PMC: 10771097.
DOI: 10.1084/jem.20231353.
High frequency of type I interferon auto-antibodies in a group of middle-aged HIV-infected patients: A cross-sectional exploratory study.
Imberti L, Magro P, Sottini A, Quaresima V, Castelli F, Quiros-Roldan E
Immun Inflamm Dis. 2023; 11(11):e1056.
PMID: 38018592
PMC: 10664390.
DOI: 10.1002/iid3.1056.
Severe acute herpes virus type 2 primo-infection and its association with anti-type 1 interferon autoantibodies.
Martinot M, Gravier S, Mohseni-Zadeh M, Fabien N, Casanova J, Puel A
Eur J Clin Microbiol Infect Dis. 2023; 42(12):1531-1535.
PMID: 37870714
DOI: 10.1007/s10096-023-04688-5.
Blockade of interferon signaling decreases gut barrier integrity and promotes severe West Nile virus disease.
Lin S, Zhao F, Janova H, Gervais A, Rucknagel S, Murray K
Nat Commun. 2023; 14(1):5973.
PMID: 37749080
PMC: 10520062.
DOI: 10.1038/s41467-023-41600-3.
Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients.
Gervais A, Rovida F, Avanzini M, Croce S, Marchal A, Lin S
J Exp Med. 2023; 220(9).
PMID: 37347462
PMC: 10287549.
DOI: 10.1084/jem.20230661.
Autoantibodies to Interferons in Infectious Diseases.
Quiros-Roldan E, Sottini A, Signorini S, Serana F, Tiecco G, Imberti L
Viruses. 2023; 15(5).
PMID: 37243300
PMC: 10223187.
DOI: 10.3390/v15051215.